Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Pinteon Therapeutics

    Client Virtual Booth

    PINTEON THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Pinteon Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1188 Centre Street Newton Center, Massachusetts, 02459
    Telephone
    Telephone
    917-607-0015
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.pinteon.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pinteon-therapeutics/about/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer's Disease and Traumatic Brain Injury
    Pinteon Extends Collaboration with Lonza for Manufacturing PNT001, a Novel Tau Antibody Targeting Alzheimer's Disease and Traumatic Brain Injury

    https://www.lonza.com/news/2021-06-24-09-00

    PRESS RELEASE
    24 Jun 2021
    Share Share
    Pinteon Therapeutics Announces $3 Million Award
    Pinteon Therapeutics Announces $3 Million Award

    https://www.businesswire.com/news/home/20210617005096/en

    BUSINESSWIRE
    17 Jun 2021
    Share Share
    Pinteon Announces $3 Million Award to Support Phase 1 Study of PNT001
    Pinteon Announces $3 Million Award to Support Phase 1 Study of PNT001

    https://www.businesswire.com/news/home/20210617005096/en

    BUSINESSWIRE
    16 Jun 2021
    Share Share
    Pinteon Announces First Patient Dosed in Phase 1 Study of PNT001
    Pinteon Announces First Patient Dosed in Phase 1 Study of PNT001

    https://www.businesswire.com/news/home/20210406005121/en

    BUSINESSWIRE
    06 Apr 2021
    Share Share
    Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001
    Pinteon Therapeutics Announces First Patient Dosed in Phase 1 Study of PNT001

    https://www.businesswire.com/news/home/20210406005121/en/Pinteon-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-PNT001-in-Patients-with-Acute-Traumatic-Brain-Injury

    BUSINESSWIRE
    06 Apr 2021
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search